https://www.pharmaradar360.com/article/field-safety-notices-8-12-june-2026-154c047bbd4667e9Pharma Surgeen2026-06-15T14:38:02.000ZField Safety Notices: 8 -12 June 2026https://www.pharmaradar360.com/article/improved-early-warning-systems-needed-to-reduce-medicines-supply-risks-says-abpi-5700e8146413aff2Pharma Surgeen2026-06-15T11:31:58.000ZImproved early warning systems needed to reduce medicines supply risks, says ABPIhttps://www.pharmaradar360.com/article/the-uk-should-seek-to-be-a-european-leader-for-rare-disease-medicine-says-new-re-d06cca08f70f94b2Pharma Surgeen2026-06-15T11:31:58.000ZThe UK should seek to be a European leader for rare disease medicine, says new reporthttps://www.pharmaradar360.com/article/abpi-celebrates-a-month-of-major-investment-commitments-into-uk-life-sciences-23c81d4b841de6ebPharma Surgeen2026-06-15T11:31:58.000ZABPI celebrates a month of major investment commitments into UK life scienceshttps://www.pharmaradar360.com/article/medicine-levy-makes-the-uk-un-investable-say-pharma-leaders-7fe6068d3e756fb9Pharma Surgeen2026-06-15T11:31:57.000ZMedicine levy makes the UK un-investable, say pharma leadershttps://www.pharmaradar360.com/article/are-nhs-patients-keeping-up-with-european-neighbours-on-access-to-new-medicines-ee7e6727b1689572Pharma Surgeen2026-06-15T11:31:57.000ZAre NHS patients keeping up with European neighbours on access to new medicines?https://www.pharmaradar360.com/article/time-to-emphasise-the-economics-in-health-economics-89a4a85efc16c1bdPharma Surgeen2026-06-15T11:31:57.000ZTime to emphasise the economics in health economicshttps://www.pharmaradar360.com/article/latest-disclosure-uk-data-higher-r-d-spend-greater-transparency-and-more-partner-256abf74bd5c3b29Pharma Surgeen2026-06-15T11:31:56.000ZLatest Disclosure UK data: higher R&D spend, greater transparency and more partnership with the NHShttps://www.pharmaradar360.com/article/aptose-presents-safety-response-and-mrd-clinical-data-from-tuscany-phase-1-2-cli-686bd460c0f0050bPharma Surgeen2026-06-15T11:30:00.000ZAptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentationhttps://www.pharmaradar360.com/article/uk-medicines-investment-the-case-for-improving-the-uk-commercial-environment-83ef8b2171ffb5dePharma Surgeen2026-06-15T11:01:56.000ZUK medicines investment: the case for improving the UK commercial environmenthttps://www.pharmaradar360.com/article/making-wales-a-destination-for-industry-clinical-trials-and-medical-research-6d7614cafd158bcbPharma Surgeen2026-06-15T11:01:55.000ZMaking Wales a destination for industry clinical trials and medical researchhttps://www.pharmaradar360.com/article/abpi-regulatory-science-symposium-2025-1a9f3c049af492c1Pharma Surgeen2026-06-15T11:01:55.000ZABPI Regulatory Science symposium 2025https://www.pharmaradar360.com/article/why-the-pharmaceutical-industry-needs-nhs-data-to-develop-new-medicines-8d4f7fc7d056463cPharma Surgeen2026-06-15T11:01:55.000ZWhy the pharmaceutical industry needs NHS data to develop new medicineshttps://www.pharmaradar360.com/article/disclosure-uk-2024-new-record-for-transparency-with-nine-in-ten-healthcare-profe-06b0cfb05a1e74c5Pharma Surgeen2026-06-15T11:01:54.000ZDisclosure UK 2024: new record for transparency, with nine in ten healthcare professionals named in databasehttps://www.pharmaradar360.com/article/speedy-anna-is-now-award-winning-91398b5a1e89d633Pharma Surgeen2026-06-15T11:01:54.000ZSpeedy Anna is now award-winninghttps://www.pharmaradar360.com/article/getting-ready-for-the-windsor-framework-ensuring-continuity-of-uk-medicines-supp-86c7e6122e7ba17dPharma Surgeen2026-06-15T11:01:53.000ZGetting ready for the Windsor Framework: ensuring continuity of UK medicines supply beyond 1 January 2025https://www.pharmaradar360.com/article/comparing-new-medicine-availability-across-europe-ecb2451c8a8d2ac8Pharma Surgeen2026-06-15T11:01:53.000ZComparing new medicine availability across Europehttps://www.pharmaradar360.com/article/mrna-technology-navigating-preclinical-research-for-rare-diseases-bc8ecb7d06617d1ePharma Surgeen2026-06-15T11:01:52.000ZmRNA technology: navigating preclinical research for rare diseaseshttps://www.pharmaradar360.com/article/june-s-story-of-sickle-cell-18cf1901f8f23588Pharma Surgeen2026-06-15T11:01:52.000ZJune’s story of sickle cellhttps://www.pharmaradar360.com/article/principles-for-analysis-and-use-of-health-data-by-abpi-members-3125668273c1226ePharma Surgeen2026-06-15T11:01:52.000ZPrinciples for analysis and use of health data by ABPI membershttps://www.pharmaradar360.com/article/mhra-s-new-international-recognition-procedure-irp-how-does-it-shape-up-2c5a3abdf7832876Pharma Surgeen2026-06-15T11:01:51.000ZMHRA’s new International Recognition Procedure (IRP): how does it shape up?https://www.pharmaradar360.com/article/my-sons-have-taught-me-more-than-i-could-ever-teach-them-db8e031147390cbaPharma Surgeen2026-06-15T11:01:51.000ZMy sons have taught me more than I could ever teach themhttps://www.pharmaradar360.com/article/tiziana-life-sciences-announces-purchase-of-shares-by-executive-chairman-53893983f98f086fPharma Surgeen2026-06-15T11:00:00.000ZTiziana Life Sciences Announces Purchase of Shares by Executive Chairmanhttps://www.pharmaradar360.com/article/light-digest-vanilla-53807db27b13040fPharma Surgeen2026-06-15T10:23:07.000ZΑπαγόρευση διακίνησης και διάθεσης του προϊόντος «LIGHT DIGEST Vanilla»https://www.pharmaradar360.com/article/xray-diam-5cm-40x40-ref-24-0460-02921cc6a8b2643fPharma Surgeen2026-06-15T10:20:25.000ZΑνάκληση παρτίδας του προϊόντος «ΤΟΛΥΠΙΑ XRAY DIAM 5CM 40X40» REF 24-0460https://www.pharmaradar360.com/article/when-one-testimony-changes-everything-mariam-soukouna-on-purpose-beyond-the-job-8d7ad8be7b526e0bPharma Surgeen2026-06-15T08:14:21.000ZWhen One Testimony Changes Everything: Mariam Soukouna on Purpose Beyond the Job Titlehttps://www.pharmaradar360.com/article/pfic-colors-making-sense-of-pfic-with-the-pfic-network-39c3dfd722905804Pharma Surgeen2026-06-15T07:37:19.000ZPFIC Colors: Making Sense of PFIC with the PFIC Networkhttps://www.pharmaradar360.com/article/meps-and-partner-organisations-call-for-investments-in-vaccine-r-d-to-support-eu-74d48e3f4e13017dPharma Surgeen2026-06-15T06:59:29.000ZMEPs and partner organisations call for investments in vaccine R&D to support EU and global health security and preparednesshttps://www.pharmaradar360.com/article/bijdragen-2b9f99aaa66dca3aPharma Surgeen2026-06-15T06:49:21.000ZBijdragenhttps://www.pharmaradar360.com/article/e-2026-337211279d2c77cfPharma Surgeen2026-06-15T06:33:47.000ZEκτέλεση προϋπολογισμού ΕΟΦ μηνός Μαϊου 2026https://www.pharmaradar360.com/article/otsuka-pharmaceutical-completes-acquisition-of-transcend-therapeutics-5db67a422f7305b3Pharma Surgeen2026-06-15T00:00:00.000ZOtsuka Pharmaceutical Completes Acquisition of Transcend Therapeuticshttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-bf1888c294fa22ebPharma Surgeen2026-06-15T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-aa6908d74f3695dcPharma Surgeen2026-06-15T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-7ec5ae1450b93e33Pharma Surgeen2026-06-15T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-5e6ccbd656da46b1Pharma Surgeen2026-06-15T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-d0aed6fd07c59e1bPharma Surgeen2026-06-15T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-9dcf211f62c53c14Pharma Surgeen2026-06-15T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-81caa1da0bd94a01Pharma Surgeen2026-06-15T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-1cd95c1c26cc7225Pharma Surgeen2026-06-15T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-4e02a3978c8c2fbbPharma Surgeen2026-06-15T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-c30621e5d1ec10f0Pharma Surgeen2026-06-15T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-eab8d5d463b2e779Pharma Surgeen2026-06-15T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-4a20ea75ebfccc3fPharma Surgeen2026-06-15T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-ddde4c80b25ac64cPharma Surgeen2026-06-15T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-6f8b283d808699a8Pharma Surgeen2026-06-15T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/which-type-of-sunscreen-is-best-160fca468c92f956Pharma Surgeen2026-06-15T00:00:00.000ZWhich Type of Sunscreen is Best?https://www.pharmaradar360.com/article/cleveland-clinic-expands-access-to-care-with-an-el-salvador-based-representative-51221623b4991881Pharma Surgeen2026-06-15T00:00:00.000ZCleveland Clinic Expands Access to Care with an El Salvador-Based Representativehttps://www.pharmaradar360.com/article/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-adc-zw19-db3d8bcb01c51eadPharma Surgeen2026-06-14T22:30:56.000ZZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026https://www.pharmaradar360.com/article/lilly-s-jaypirca-pirtobrutinib-significantly-reduced-the-risk-of-disease-progres-ab454f660b9aedc2Pharma Surgeen2026-06-14T07:15:00.000ZLilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLhttps://www.pharmaradar360.com/article/lilly-to-present-initial-clinical-data-for-first-in-class-type-ii-jak2-inhibitor-1d944c5e76d37a00Pharma Surgeen2026-06-13T15:15:00.000ZLilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting